NCT03042689View on ClinicalTrials.gov

Study of Regorafenib in Patients With Advanced Myeloid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

April 17, 2017

Primary Completion Date

September 1, 2021

Study Completion Date

February 27, 2023

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Regorafenib

Regorafenib will be administered on a 28 day cycle Treatment will be administered on outpatient basis at a pre-determine dosage.

Trial Locations (1)

02114

Massachusetts general Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Massachusetts General Hospital

OTHER